Pet Service Holding Achieves 14% Revenue Growth in the First Half of 2025
Pet Service Holding (Paris:ALPET), the only company listed on Euronext Growth in Europe that is fully dedicated to pet health and well-being, achieved a 14% revenue growth in the first half of 2025 compared to the same period in 2024, reaching c. €7 million in revenue.
This solid growth highlights Pet Service Holding's strong position in a rapidly expanding European pet market. The number of households with pets continues to rise; currently, more than 80 million European households have a named pet. At the same time, spending on pet food, health, and innovative solutions is increasing. According to Bloomberg, this trend is expected to continue at least through 2030.
'Our growth demonstrates that we are successfully responding to structural market developments,' said Ron van Veldhoven, CEO of Pet Service Holding. 'Thanks to our integrated approach, we offer a comprehensive range of high-quality products and services that optimally support pets and their owners.'
Pet Service Holding combines veterinary pharmacies, wholesalers, online shops, and digital platforms into one powerful ecosystem. The company provides solutions in the areas of nutrition, health, and smart technology for pets.
Pet Service Holding is listed on Euronext Growth under the ticker ALPET.
This listing, effective since 28 July 2025, reflects the company's efforts to enhance its visibility and corporate governance. Moreover, it provides the company with efficient access to capital for further growth and strategic acquisitions.
About Pet Service Holding
Pet Service Holding NV is a leader in the field of animal care in the Netherlands. We aim to distinguish ourselves in this competitive market by bringing together a range of services and capitalizing on its valuable experience and expertise in this field. With a focus on animal supplies and nutrition and supplies for veterinary practices, we are well positioned to meet the needs of animals and their owners in Europe.
Ticker: ALPET (Euronext Growth Paris) - ISIN: NL0015001HZ9
Also listed on: NXchange Amsterdam (ISIN: NL00150004O8).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Smarsh Named to Inc. 5000 for 18th Consecutive Year
Prestigious annual ranking of the most successful private companies in America spotlights 3-year revenue growth of 114% at Smarsh PORTLAND, Ore., August 12, 2025--(BUSINESS WIRE)--Smarsh, the global leader in digital communications compliance and intelligence, today announced it has been named to the Inc. 5000 list of the fastest-growing private companies in America for the 18th year in a row. This remarkable achievement underscores nearly two decades of sustained growth, innovation, and customer impact in one of the most essential and rapidly evolving sectors of enterprise technology. Smarsh is one of only two organizations in the history of the Inc. 5000 to receive this recognition 18 times. Where Vision Meets Execution "Smarsh is honored to be recognized on the Inc. 5000 list for the eighteenth consecutive year," said Kim Crawford Goodman, Chief Executive Officer of Smarsh. "This achievement reflects how we've redefined sustainable growth and delivered lasting value for customers in financial services, government and beyond. It also speaks to our relentless pursuit of excellence across every sector we serve. By combining transformative technology with a forward-looking vision, we help our customers stay secure, competitive, and confident—especially as they navigate shifts like the rise of AI. This recognition is a testament to our people, our partners, and the culture of innovation and leadership that drives our continued success." Smarsh ranked No. 3437 on this year's list, reporting a three-year (2021–2024) revenue growth rate of 114%. The company's momentum is fueled by major innovations in compliance AI, including the industry's first solution for Microsoft Copilot Capture and an Intelligent Agent that applies cutting-edge AI to find risk in communications data efficiently. Smarsh supports a wide range of organizations, from emerging advisory firms to 18 of the top 20 global banks, helping them meet the requirements of the SEC, FINRA, and other regulators around the world. Execution That Delivers Results This recognition comes amid a year of strong momentum for Smarsh, marked by multiple accolades for its innovation, vision and culture. Recent honors include the 2025 Silver Globee Award for "Best Use of AI in Finance," a spot on the 2025 AIFINTECH100 list of the world's most innovative AI companies in financial services, and recognition as a 2025 USA TODAY Top Workplace. These accomplishments demonstrate leadership in delivering secure, scalable and future-ready solutions for the world's most regulated industries. "Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor-in-chief of Inc. "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." For complete results of the Inc. 5000, visit About Smarsh Smarsh enables companies to transform oversight into foresight by surfacing business-critical signals in their digital communications. Serving the top banks, insurers, investment firms, and government agencies worldwide, Smarsh delivers cloud-native solutions that help organizations stay compliant, mitigate risk, and unlock the value of their communications data. Learn more at or follow us on LinkedIn. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit View source version on Contacts Media Contact press@ Sign in to access your portfolio
Eater
10 minutes ago
- Eater
Popular Flushing Rice Roll Stand Is Heading Into Brooklyn
is a born-and-raised New Yorker who is an editor for Eater's Northeast region and Eater New York, was the former Eater Austin editor for 10 years, and often writes about food and pop culture. Joe's Steam Rice Roll, the popular Flushing rice roll stand, is expanding with its third location, to Sunset Park at 774 58th Street, near Eighth Avenue. No opening date has been announced yet, but an Instagram post on July 30 states that it is 'coming soon.' Eater has reached out for more information. Owner Joe Rong is known for his Cantonese chang fen, where the rice cakes are produced with an electric-powered stone mill from China. The filling menu is simple with five options ranging from curry fish balls to pork, plus additions like corn and scallions. He first opened Joe's in Flushing in 2017, followed by Canal Street in 2018. There had been an outpost on St. Marks Place, but that closed. There's an Uptown location on the Upper West Side that opened in 2020. The new location appears to be taking over the sole New York location of Los Angeles Taiwanese tea shop chain Yi Fang Taiwan Fruit Tea. Very new Manhattan restaurant changes its name One of summer's hot new dining destinations in the city has already changed its name after less than a month in service. Haymarket, the modern European restaurant with Caribbean flair in Chelsea, is now called Markette. A rep tells Eater this is because there are similarly named businesses in the area. Within a two-block radius, there's gastropub Haymaker Bar, condo building Haymarket, and the Haymarket Media company. Co-owners chef India Doris and Alex Pfaffenbach had originally chosen the name Haymarket to honor a 19th-century dance hall in the borough and the famous London district. Longtime Manhattan bakery up for sale A longtime Tribeca bakery is up for sale now. Owner Madeline Laciani is looking to sell her 33-year-old Duane Park Patisserie because she wants to retire, as reported by Tribeca Citizen. Laciani had been baking in New York for some time, per the publication. She had opened her first bakery in 1997 with her then-husband, Patisserie Lanciani, and ran two locations of it after they got divorced until it closed. Then she opened Duane Park in 1992, becoming known for its cakes and cupcakes. Eater NY All your essential food and restaurant intel delivered to you Email (required) Sign Up By submitting your email, you agree to our Terms and Privacy Notice . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Business Wire
10 minutes ago
- Business Wire
Techcyte and Modella AI Announce a Research Collaboration with Modella AI's State-of-the-Art Agentic and Generative AI-Powered Diagnostic Pathology Platform
OREM, Utah--(BUSINESS WIRE)-- Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion ™ (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program. This collaboration brings together Modella AI's groundbreaking research-use only AI co-pilot for pathologists, PathChat ™, with Techcyte's integrated, cloud-based digital pathology platform—supporting the advancement of workflow efficiency and expanding access to advanced AI-powered pathology tools for research. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. Modella AI is a biomedical artificial intelligence company focused on improving pathology through generative and agentic AI. Its flagship research product, PathChat, enables intelligent interactions with digital slides—offering capabilities such as report summarization, image interpretation, and contextual question answering. An advanced research-use only version of the tool, PathChat DX, has been granted U.S. Food and Drug Administration Breakthrough Device Designation, reflecting the device's potential to provide a more effective diagnosis of a life-threatening or irreversibly debilitating condition. While this designation recognizes the potential of the technology, any use of PathChat within the Techcyte Fusion platform remains for research use only and is not intended for clinical diagnostic purposes. 'Modella AI's commitment to innovation, including agentic AI, and Techcyte's unified pathology platform create a powerful research combination,' said Matt Smith, Chief Strategy Officer at Techcyte. 'Together, our goal is delivering practical AI that pathologists can trust and that seamlessly integrates into their digital workflows.' 'We're excited to partner with Techcyte to bring our pathology-native AI to a broader research audience,' said Jill Stefanelli, President, Cofounder, and Chief Executive Officer at Modella AI. 'Integrating PathChat into the Fusion research platform supports the exploration of AI-assisted workflows in pathology and reflects our shared commitment to advancing digital innovation in the lab.' The integration of PathChat into Techcyte Fusion represents a significant step forward in operationalizing next-generation AI. As pathology workloads increase and case complexity grows, this collaboration represents an important step toward exploring AI capabilities in digital pathology research settings—all within the familiar Techcyte platform. For more information about the Techcyte Fusion Partner Program, visit About Techcyte Techcyte is aiming to transform the practice of pathology through a unified, AI-powered digital platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab. By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment. Visit for more information. Techcyte's anatomic and clinical pathology platform is for Research Use Only in the United States. About Modella Modella AI ( is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. By combining expertise in artificial intelligence and pathology, Modella AI aims to deliver innovative solutions that empower clinicians, improve patient outcomes, and transform medical workflows. Disclaimer: PathChat ™, PathChat ™ DX and the Techcyte Fusion ™ platform are research-use only devices and are not commercially available in the United States (as they are not FDA cleared or approved). The Techcyte Fusion platform is commercially available in Europe for diagnostic use. The FDA Breakthrough Device Designation for PathChat DX does not imply FDA clearance or approval. This press release contains forward-looking statements based on current assumptions and forecasts. Modella AI and Techcyte assume no obligation to update these statements to reflect future events or developments.
